Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Finally, a Yes for Yescarta

Posted 5 August 2021 AM

Gilead's Yescarta has become the second CAR-T therapy in Australia to win government funding, following an arduous 19-month wait after it was recommended by MSAC.

The news has been welcomed by clinicians and patients alike, eager for another treatment for the four aggressive lymphoma subtypes for which it has been approved.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Approvals Action
Melb pharma registers first copy
Long list of generic versions of PBS-listed drugs